86 A phase I/II open-label study to assess the safety, pharmacokinetic profile, and preliminary antiviral effects of ost-577 (a human anti-hepatitis b surface antigen monoclonal antibody) administered to patients who are persistently hepatitis b antigen seropositive: DP Paar, MD, BM Montgomerie, RN, P Nadler, MD, ER Schiff, MD and RB Pollard, MD. The University of Texas Medical Branch at Galveston, Galveston, TX, USA; Protein Design Labs, Mountain View, CA, USA; the University of Miami, Miami, FL, USA